The right to participate in high-risk research

Here, I argue that institutional review boards should never reject a study because it poses too high a risk to participants, and that their role should be confined to ensuring that risks and any potential benefits are fully explained to potential participants. Everyone should have the right to parti...

Full description

Saved in:
Bibliographic Details
Published inThe Lancet (British edition) Vol. 383; no. 9921; pp. 1009 - 1011
Main Author Shaw, David, Dr
Format Journal Article
LanguageEnglish
Published Kidlington Elsevier Ltd 15.03.2014
Elsevier
Elsevier Limited
Subjects
Biological and medical sciences
Biomedical Research - ethics
Clinical trials
Ethics Committees, Research - ethics
Ethics, Medical
General aspects
Humans
Industrialized nations
Internal Medicine
Medical sciences
Participation
Patient Participation
Patient Rights - ethics
Patient Selection - ethics
Research Subjects
Review boards
Risk Assessment - ethics
Studies
Medicine
Right
Participation
High risk
Scientific research
Online AccessGet full text

Cover

More Information
Summary:Here, I argue that institutional review boards should never reject a study because it poses too high a risk to participants, and that their role should be confined to ensuring that risks and any potential benefits are fully explained to potential participants. Everyone should have the right to participate in research without paternalistic decisions about risk being made on their behalf.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(13)61575-5